Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

26.97 (USD) • At close April 30, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2025 Q12024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q1
Revenue 137.785122.536112.214108.63179.85883.39567.04671.47348.34561.88499.13526.97232.18918.74512.0957.70400000000000000000
Cost of Revenue 61.658-62.22649.41642.45531.53826.75926.39921.6857.03614.23211.565.0294.2193.8672.7672.4660.8830000000000000000
Gross Profit 76.127184.76262.79866.17648.3256.63640.64749.78841.30947.65287.57521.94327.9714.8789.3285.238-0.8830000000000000000
Gross Profit Ratio 0.5531.5080.560.6090.6050.6790.6060.6970.8540.770.8830.8140.8690.7940.7710.6800000000000000000
Reseach & Development Expenses 19.32535.21526.05723.89826.1819.81617.10623.76715.17214.3916.48513.79820.81727.43319.23623.94528.68337.39831.41922.32420.90122.88622.01430.84859.25336.12220.64417.212.6329.93114.0089.2723.145
General & Administrative Expenses 0000000000000000015.511.7999.5368.4869.6958.4328.4418.3948.0135.5154.3273.712.782.2412.121.903
Selling & Marketing Expenses 000000000000000001.40-0.6-0.8000000000000
SG&A 43.5340.53546.39942.39538.68236.73934.46829.17529.04527.21524.67723.84122.21822.74120.75921.84820.615.511.7999.5368.4869.6958.4328.4418.3948.0135.5154.3273.712.782.2412.121.903
Other Expenses 0128.31102.4212.2662.3692.4281.9158.2880.7946.9373.6728.2540.8352.7672.46600000000000000000
Operating Expenses 62.855204.06172.45666.29364.86256.55551.57452.94252.50541.60541.16241.31151.28951.00939.99545.79349.28352.89843.21831.8629.38732.58130.44639.28967.64744.13526.15921.52716.3432.71116.24911.3925.048
Operating Income 13.272-19.299-9.658-0.117-16.5420.081-10.927-3.154-11.1966.04746.413-19.368-23.251-36.131-30.667-40.555-49.283-52.898-43.218-31.86-29.387-32.581-30.446-39.289-67.647-44.135-26.159-21.527-16.34-32.711-16.249-11.392-5.048
Operating Income Ratio 0.096-0.157-0.086-0.001-0.2070.001-0.163-0.044-0.2320.0980.468-0.718-0.722-1.928-2.536-5.26400000000000000000
Total Other Income Expenses Net 2.2932.322.4572.4212.2662.3692.4281.9151.8320.7940.3220.1030.0340.0770.0050.0060.0090.030.0490.2660.7891.131.3861.7241.8091.7271.6221.0660.3050.1330.1690.1530.074
Income Before Tax 15.565-16.979-7.2012.304-14.2762.45-8.499-1.239-9.3646.84146.735-19.265-23.285-36.054-30.662-40.549-49.274-52.868-43.169-31.594-28.598-31.451-29.06-37.565-65.838-42.408-24.537-20.461-16.035-32.578-16.08-11.239-4.974
Income Before Tax Ratio 0.113-0.139-0.0640.021-0.1790.029-0.127-0.017-0.1940.1110.471-0.714-0.723-1.923-2.535-5.26300000000000000000
Income Tax Expense 7.026-8.0915.4926.2123.428-22.7875.356-16.2112.9062.38-177.3580.7161.9250.279-0.1181.0140.210.7890.6675.875-2.1790.346-2.002-0.374-0.0170.172-0.131-0.202-0.0530.123-0.051-0.036-0.033
Net Income 8.539-8.888-12.693-3.908-17.70425.237-13.85514.972-12.274.461224.093-19.981-25.21-36.333-30.544-41.563-49.484-53.657-43.836-37.469-26.419-31.797-27.058-37.191-65.821-42.58-24.406-20.259-15.982-32.701-16.029-11.203-4.941
Net Income Ratio 0.062-0.073-0.113-0.036-0.2220.303-0.2070.209-0.2540.0722.26-0.741-0.783-1.938-2.525-5.39500000000000000000
EPS 0.12-0.12-0.18-0.055-0.250.36-0.20.21-0.180.0643.23-0.29-0.36-0.53-0.44-0.61-0.72-0.79-0.66-0.65-0.48-0.58-0.49-0.68-1.27-0.88-0.51-1.11-0.34-1.01-0.49-0.35-0.15
EPS Diluted 0.11-0.12-0.18-0.055-0.250.35-0.20.21-0.180.0633.18-0.29-0.36-0.53-0.44-0.61-0.72-0.79-0.66-0.65-0.48-0.58-0.49-0.68-1.27-0.88-0.51-1.11-0.34-1.01-0.49-0.35-0.15
EBITDA 13.272-18.899-9.6580.313-16.0760.317-10.324-2.552-10.67.92346.413-18.717-22.663-35.463-30.009-39.838-48.971-52.331-42.569-31.265-28.793-32.015-29.923-38.781-67.176-43.881-26.147-21.515-16.332-32.703-16.241-11.386-5.042
EBITDA Ratio 0.096-0.154-0.0860.003-0.2010.004-0.154-0.036-0.2190.1280.468-0.694-0.704-1.892-2.481-5.17100000000000000000